Tang Wei, Zhang Yufeng, Cui Sijia, Yi Fan
Department of Pharmacology, The Key Laboratory of Infection and Immunity of Shandong Province, School of Basic Medical Sciences, Shandong University, Jinan, China.
Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Health, and The State and Shandong Province Joint Key Laboratory of Translational Cardiovascular Medicine, Qilu Hospital, Shandong University, Jinan, China.
Kidney Dis (Basel). 2022 Sep 12;8(5):368-380. doi: 10.1159/000526208. eCollection 2022 Nov.
Kidney diseases are a prevalent health problem worldwide. Although substantial progress has been made in understanding the pathophysiology of kidney disease, currently there is no satisfactory clinical treatment available to prevent or treat kidney disease. Therefore, strategies to establish early diagnosis, identify the key molecules, and develop novel therapeutic interventions to slow the progression of kidney diseases and reduce their complications are encouraged.
The growth factors play a crucial role in the development of kidney diseases. The altered levels of growth factors are usually detected in circulation and urine in the disease course. A growing body of studies has suggested that growth factors, receptors, and related regulators are promising biomarkers for the diagnosis and/or prognosis and potential therapeutic targets for the treatment of kidney diseases. In this review, we summarize recent advances in the potential applications of growth factors for diagnostic biomarkers and therapeutic targets in kidney diseases and highlight their performances in clinical trials.
Most diagnostic and therapeutic strategies targeting growth factors are still far from clinical implementation. The better understanding of growth factor-regulated pathophysiology and the progress of new intervention approaches are expected to facilitate the clinical translation of growth factor-based diagnosis and therapy of kidney diseases.
肾脏疾病是全球普遍存在的健康问题。尽管在理解肾脏疾病的病理生理学方面已取得重大进展,但目前尚无令人满意的临床治疗方法来预防或治疗肾脏疾病。因此,鼓励采取策略以建立早期诊断、识别关键分子,并开发新的治疗干预措施来减缓肾脏疾病的进展并减少其并发症。
生长因子在肾脏疾病的发展中起关键作用。在疾病过程中,通常可在循环系统和尿液中检测到生长因子水平的改变。越来越多的研究表明,生长因子、受体及相关调节因子有望成为肾脏疾病诊断和/或预后的生物标志物以及潜在的治疗靶点。在本综述中,我们总结了生长因子在肾脏疾病诊断生物标志物和治疗靶点潜在应用方面的最新进展,并强调了它们在临床试验中的表现。
大多数针对生长因子的诊断和治疗策略仍远未应用于临床。对生长因子调节的病理生理学的更深入理解以及新干预方法的进展有望促进基于生长因子的肾脏疾病诊断和治疗的临床转化。